A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients. The new study will be presented at the European ...
Hosted on MSN3mon
Blood clot drug taken by millions of AmericansSoriot said that IoT technology is already helping patients get access to drugs such as its platelet therapy, Brilinta. Soriot said: “We can leverage digital tools to better treat patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback